Olli Kallioniemi is Professor in Molecular Precision Medicine at the Karolinska Institutet and Director of the Science for Life Laboratory (www.SciLifeLab.se), a national infrastructure for life sciences in Sweden since 2015. Professor Kallioniemi received his M.D. in 1984, Ph.D. in 1988 and specialty training in laboratory medicine at the University of Tampere in Finland. He undertook a postdoc at UC San Francisco in 1990-1992 and was appointed faculty at the National Human Genome Research Institute, at the NIH (1995-2002).
He was the founding director of the Medical Biotechnology unit at Turku, Finland at the VTT Technical Research Centre and University of Turku (2002-2008). He was the Founding Director of FIMM – the Institute for Molecular Medicine Finland (www.fimm.fi) and professor at the University of Helsinki in 2007-2015. FIMM is part of the Nordic EMBL partnership in Molecular Medicine. Professor Kallioniemi is an author of 358 publications, a member of the editorial board of six journals and has been an invited key note lecturer in over 150 meetings during the past five years. He has supervised 23 doctoral theses and has been an advisor to 27 postdocs.
Professor Kallioniemi is an inventor and co-inventor of 24 issued patents, with a focus on diagnostic technology development, such as FISH, CGH, tissue microarrays, cell-based RNAi microarrays and bioinformatic methods. His current research is focussing on individualized systems medicine to promote precision care of cancer patients. Professor Kallioniemi is a member of EMBO, the National Academy of Sciences (Finland), European Academy of Cancer Sciences and an elected member of The Nobel Assembly.